A Phase 2, Open-label, Multicenter Multi-cohort Study to Evaluate the Efficacy and Safety of Anitocabtagene Autoleucel in Participants With Newly Diagnosed Multiple Myeloma

The goal of this clinical trial is to learn if anitocabtagene autoleucel following induction therapy works to treat adult participants with newly diagnosed multiple myeloma. The main objectives of this clinical trial are:
* To determine the incidence and severity of all adverse events (AEs).
* To determine the proportion of patients achieving undetectable minimal residual disease (uMRD) negative-CR rate (minimum 10 to -5) at 12 months (+/- 3 months) after enrollment.
Participants will receive induction therapy with a quadruplet regimen including a proteasome inhibitor (Bortezomib [V]), immunomodulatory drug (Lenalidomide [R]), dexamethasone [d] and anti-CD38 monoclonal antibody (Daratumumab [D] or Isatuximab [Isa]) followed by anitocabtagene autoleucel. Participants in Cohorts A and B will receive lenalidomide maintenance therapy following infusion with anitocabtagene autoleucel.

开始日期2025-06-30

申办/合作机构-

NCT06626919

/ Recruiting临床1期

A Phase 1 Study of Anitocabtagene Autoleucel for the Treatment of Subjects With Non-oncology Plasma Cell-related Diseases

A Phase 1 dose-escalation study designed to evaluate the safety, tolerability, and preliminary efficacy of anito-cel in subjects with generalized myasthenia gravis (GMG). Anitocabtagene autoleucel (anito-cel) is a BCMA-directed CAR-T cell therapy.

开始日期2025-04-30

申办/合作机构

Arcellx, Inc.

NCT06413498

/ Active, not recruiting临床3期

A Phase 3, Randomized, Open-Label Study to Compare the Efficacy and Safety of Anitocabtagene Autoleucel Versus Standard of Care Therapy in Participants With Relapsed/Refractory Multiple Myeloma

The goal of this study (iMMagine-3) is to compare the study drug, anitocabtagene autoleucel to standard of care therapy (SOCT) in participants with relapsed/refractory multiple myeloma who have received 1 to 3 prior lines of therapy, including an anti-CD38 monoclonal antibody and an immunomodulatory drug.
The primary objective of this study is to compare the efficacy of anitocabtagene autoleucel versus SOCT in participants with RRMM.

开始日期2024-08-23

申办/合作机构

Kite Pharma, Inc.

[+1]

100 项与阿尼托卡布他基因自体淋巴细胞相关的临床结果

登录后查看更多信息

100 项与阿尼托卡布他基因自体淋巴细胞相关的转化医学

登录后查看更多信息

100 项与阿尼托卡布他基因自体淋巴细胞相关的专利（医药）

登录后查看更多信息

项与阿尼托卡布他基因自体淋巴细胞相关的文献（医药）

2023-03-14·Blood Advances2区 · 医学

Phase 1 study of CART-ddBCMA for the treatment of subjects with relapsed and refractory multiple myeloma

2区 · 医学

Article

作者: Shaw, Kit ; Raje, Noopur ; Heery, Christopher ; Bishop, Michael R. ; O’Donnell, Elizabeth K. ; Daley, Heather ; Frigault, Matthew J. ; Jakubowiak, Andrzej ; Rosenblatt, Jacalyn ; Maus, Marcela V. ; Griffin, Faith ; Nikiforow, Sarah ; Yee, Andrew J. ; Logan, Emma ; Cook, Daniella ; Avigan, David E. ; Cornwell, Christine ; Shen, Angela

Abstract:

Relapsed and refractory multiple myeloma (RRMM) is a plasma cell neoplasm defined by progressively refractory disease necessitating chronic and increasingly intensive therapy. Despite recent advances, limited treatment options exist for RRMM. This single-arm, open label phase 1 study aimed to evaluate the safety of novel B-cell maturation antigen (BCMA)-targeting chimeric antigen receptor (CAR) T construct that leverages a completely synthetic antigen-binding domain (CART-ddBCMA), which was specifically engineered to reduce immunogenicity and improve CAR cell surface stability. Thirteen patients ≥18 years with RRMM who received at least 3 prior regimens of systemic therapy were enrolled in the study. Patients received a single dose of 100 × 106 CART-ddBCMA (DL1) or 300 × 106 CART-ddBCMA (DL2) following standard lymphodepleting chemotherapy. The primary endpoints of the study were to evaluate the incidence of treatment emergent adverse events, including dose-limiting toxicities, and establish a recommended phase 2 dose. Results showed that CART-ddBCMA was well tolerated and demonstrated a favorable toxicity profile. Only 1 case of grade ≥3 cytokine release syndrome and 1 case of immune effector cell–associated neurotoxicity were reported; both were at DL2 and were manageable with standard treatment. No atypical neurological toxicities and Parkinson disease-like movement disorders were observed. The maximum tolerated dose was not reached. All infused patients responded to CART-ddBCMA, and 9/12 (75%) patients achieved complete response/stringent complete response. Responses deepened over time, and at the time of last data-cut (median follow-up 56 weeks), 8/9 (89%) evaluable patients achieved minimal residual disease negativity. In conclusion, the findings demonstrate the safety of CART-ddBCMA cells and document durable responses to CART-ddBCMA in patients with RRMM. This trial was registered at www.clinicaltrials.gov as #NCT04155749.

2022-07-05·Molecular cancer therapeutics

Preclinical Efficacy of BCMA-Directed CAR T Cells Incorporating a Novel D Domain Antigen Recognition Domain

Article

作者: Richman, Laura K. ; Witter, Alexandra R. ; Tice, David A. ; Zaritskaya, Liubov ; Hilbert, David M. ; Buonato, Janine M. ; Edwards, Justin P. ; Gupta, Ankit ; LaFleur, David W.

Abstract:

Chimeric antigen receptor (CAR) T-cell therapies directed against B-cell maturation antigen (BCMA) have shown compelling clinical activity and manageable safety in subjects with relapsed and refractory multiple myeloma (RRMM). Prior reported CAR T cells have mostly used antibody fragments such as humanized or murine single-chain variable fragments or camelid heavy-chain antibody fragments as the antigen recognition motif. Herein, we describe the generation and preclinical evaluation of ddBCMA CAR, which uses a novel BCMA binding domain discovered from our D domain phage display libraries and incorporates a 4-1BB costimulatory motif and CD3-zeta T-cell activation domain. Preclinical in vitro studies of ddBCMA CAR T cells cocultured with BCMA-positive cell lines showed highly potent, dose-dependent measures of cytotoxicity, cytokine production, T-cell degranulation, and T-cell proliferation. In each assay, ddBCMA CAR performed as well as the BCMA-directed scFv-based C11D5.3 CAR. Furthermore, ddBCMA CAR T cells demonstrated in vivo tumor suppression in three disseminated BCMA-expressing tumor models in NSG-immunocompromised mice. On the basis of these promising preclinical data, CART-ddBCMA is being studied in a first-in-human phase I clinical study to assess the safety, pharmacokinetics, immunogenicity, efficacy, and duration of effect for patients with RRMM (NCT04155749).

Turkish Journal of Hematology

2025 Update of Cellular Immunotherapy for Plasma Cell Disorders

Review

作者: Beksac, Meral ; Vural, Ece

Despite progression-free survival in multiple myeloma (MM) patients extending to 17 years due to contemporary quadruplet induction therapies, there remains a necessity for novel products in the treatment of high-risk patients. BCMA, GPRC5D, FcRH5, SLAMF7, and TACI are the principal chimeric antigen receptor T (CAR-T) cell target molecules, with dual-target treatments under development to enhance treatment efficacy. Ide-cel and cilta-cel are CAR-T cells directed against BCMA, having received approval from the U.S. Food and Drug Administration for relapsed/refractory MM based on the phase 2 KarMMa and CARTITUDE trials, respectively. Research is currently being conducted on the administration of these products in newly diagnosed patients and for maintenance therapy. Additional anti-BCMA targeted medicines, including LCAR-B38M, completely humanized CAR-T (FHVH-T), P-BCMA-ALLO-1, ALLO-715, and anti-BCMA CAR-NK, provide promising treatment options. Moreover, the anti-CD19 Fast-CAR, designed to shorten production time, and PHE885, which possesses in vivo proliferation capability, are regarded as very efficacious. Arlo-cel, developed for the significant target GPRC5D, has demonstrated efficacy compared to conventional treatments. The development of academic CAR-T products such as ARI0002h, HBI0101, eque-cel, zevor-cel, anito-cel, and Sleeping Beauty (utilizing a non-viral vector) have importance due to their accessibility and cost-effectiveness. Real-world data have demonstrated comparable efficacy and safety outcomes in both academic and commercial CAR-T research. CAR-T cell studies are also being undertaken for smoldering MM and amyloid light-chain (AL) amyloidosis. CAR-PRISMM and CAR-HiRiSMM are regarded as extremely effective and safe therapies for patients with high-risk smoldering MM. NXC-201, which targets BCMA, has been developed for AL amyloidosis. Notwithstanding these promising outcomes, numerous difficulties still confront CAR-T therapy. These factors may be related to the tumor, the patient, and/or the CAR-T product. To overcome these issues, new strategies are being implemented, including combination therapy and the incorporation of gamma-secretase inhibitors. In conclusion, CAR-T treatments have evolved into an effective therapy modality and are anticipated to be utilized in earlier treatment phases in the future. The CRISPR gene editing method contributes to future perspectives.

344

项与阿尼托卡布他基因自体淋巴细胞相关的新闻（医药）

2026-08-20

·同写意

南京驯鹿，让澳大利亚不再神秘

CPIC 2026已于7月24日在上海国家会展中心圆满落幕。本届大会从内容策划、嘉宾邀约与对接，到视觉设计、展商招募与布展，乃至文字报道、视频制作及晚宴晚会，均由“同写意”团队全程自主策划与执行。依托专业的整合能力，同写意现面向行业承接学术会议、庆典活动、会务会展、媒体公关、行业咨询及企业内训等多元化业务合作。 2026年8月20日，驯鹿生物宣布，澳大利亚药品管理局（TGA）正式受理伊基奥仑赛注射液（FUCASO）纳入澳大利亚治疗用品登记册（ARTG）的生物制品上市注册申请，进入评估阶段。适应症还是那个：既往至少3线治疗后进展的复发/难治性多发性骨髓瘤（r/r MM）成人患者。这条消息放进驯鹿自己的时间线里，只是又一步。过去两年，这家南京公司的国际化节奏不像一家Biotech公司：2025年1月，新加坡卫生科学局（HSA）受理FUCASO的新药申请，这是它递交的第一个境外上市申请；2025年2月，香港卫生署受理，FUCASO成为香港首个受理的国产CAR-T；2025年3月，澳门获批，第一个境外NDA落地；2025年7月，驯鹿从信达生物买回福可苏的全球商业化权益，信达以相同价格入股18%成为战略股东，产品全球化的决定权回到自己手里；2025年11月，香港获批上市；2026年6月，新加坡正式批准FUCASO上市，国产CAR-T首次在大中华区以外获批；2026年8月，又宣布收购新加坡CAR-T公司MediSix，把4-1BB共刺激域技术的开创者之一收入囊中。但放进整个行业的语境里，这次澳洲受理有一个容易被忽略的信号——澳大利亚，这个中国创新药讲了十几年”临床故事”的地方，正在被重新标定为”商业化战场”。 TONACEA 01 澳洲市场，中国创新药还没怎么赢过先看近三年中国创新药在澳大利亚上市的成绩单。真正算得上获批上市的案例，一只手数得过来。最标志性的是君实生物。2025年1月17日，君实宣布特瑞普利单抗的上市许可申请获TGA批准，用于两项鼻咽癌适应症。这款药走的是Project Orbis——美国FDA肿瘤学卓越中心发起的多监管机构联合审评机制，特瑞普利单抗是首个被纳入该项目的国产肿瘤药，还拿了TGA孤儿药资格。它同时是澳大利亚首个且唯一用于鼻咽癌的肿瘤免疫治疗药物。复宏汉霖的汉曲优（曲妥珠单抗生物类似药）也已进入澳大利亚，连同美国、英国、加拿大、欧盟等地，这款药已经在全球50多个国家和地区上市。但除此之外，能数出来的就不多了。据中国食品药品网盘点，2024年有14款中国创新药在全球多地获批，覆盖欧洲、日本、美国以及印度尼西亚、澳大利亚、缅甸等新兴市场——澳大利亚只是其中一档。截至2024年底，中国原研创新药在海外获批累计18款，绝大多数集中在欧美。换句话说，过去几年，澳大利亚对中国创新药的主要角色不是上市目的地，而是临床试验桥头堡。行业数据显示，中国企业海外开展的临床试验，除美国外最集中的就是澳大利亚——单中心145项、多中心73项。药企看中它什么？临床启动快、成本可控、数据能被FDA和EMA接受。很多国产新药的第一份人体数据，是在悉尼或墨尔本产生的。获批案例少，原因也直白：澳洲市场人口两千多万，容量摆在那里，远不如美国、欧盟有想象力；中国药企出海的优先序，一直是美国优先、欧洲次之、东南亚和新兴市场兜底，澳洲排在靠后的位置。它更像一个”跳板”而非”终点”。 TONACEA 02 TGA到底是什么这就要说到澳大利亚的药监体系。TGA（Therapeutic Goods Administration）隶属澳大利亚联邦卫生部，依据《治疗用品法案1989》对药品、医疗器械和生物制品实施监管。它的核心是ARTG——澳大利亚治疗用品登记册，任何产品想上市，必须先被列入ARTG。处方药走注册路径，生物制品（细胞治疗产品归此类）另有专门的生物制品监管框架，从生产、检验到上市后监控都有独立要求。 TGA在国际监管体系里的地位值得多说两句。它是全球公认的”严格监管机构”（SRA）之一。这个词在WHO的信赖体系里是硬通货——TGA的审评结论可以被多个国家直接采信。同时TGA认可FDA、EMA等机构的审评结果，符合条件的可以走简化路径，也参与Project Orbis这类国际合作审评。对一家中国biotech来说，产品能过TGA这一关，等于在全球监管体系里存下一笔”信用”。对细胞治疗产品，TGA还有一层特殊要求：它是”活的药物”，生物制品框架对生产地点、供应链和上市后追踪都有更细的规定。海外工厂若已通过FDA、EMA或PIC/S成员的检查，TGA接受相应检查报告，可免去现场审计——这对在国内生产、向澳洲出口的中国企业是实质性的便利。上市之后是支付。澳大利亚有药品福利计划（PBS），高值创新药另有Highly Specialised Therapies Program——单患者治疗费用20万澳元级别、经过MSAC卫生技术评估的产品，走这个通道获得联邦与州政府共同出资。澳洲市场不大，但CAR-T这种高价治疗，在这里是有真实公共支付通道的。 TONACEA 03 澳洲不是空白市场 FUCASO是来打擂的这里有一个很多人忽略的事实：澳大利亚已经有4款自体CAR-T获批上市。最早的是诺华Kymriah，2018年12月获TGA批准，用于儿童和年轻成人B细胞急性淋巴细胞白血病、以及成人复发/难治性弥漫大B细胞淋巴瘤，也是澳洲首款获批并获得公共资助的CAR-T。随后吉利德的Yescarta获批治疗大B细胞淋巴瘤，Tecartus获批治疗套细胞淋巴瘤。这三款都已进入Highly Specialised Therapies Program，由公共资金买单。多发性骨髓瘤赛道，2023年6月7日，强生/传奇的CARVYKTI（西达基奥仑赛，cilta-cel）获TGA批准，用于至少3线治疗后的复发/难治性多发性骨髓瘤——和FUCASO这次申报的适应症完全一致。这句话值得展开。传奇生物是中国细胞治疗出海的标杆，CARVYKTI由传奇研发、强生负责全球商业化，2022年获FDA批准后一路成长为”十亿美元分子”。它先于FUCASO四年进入澳大利亚，把监管、支付、临床使用的全链条都跑了一遍。这条赛道的热度还不止于此。2026年2月，吉利德宣布以78亿美元收购BCMA CAR-T新秀Arcellx，其核心产品anito-cel与福可苏同靶点同适应症，FDA的审评决定日就定在今年底。全球最舍得花钱的MNC，都在为BCMA CAR-T加注。所以驯鹿这次递进去的，不是一份”空白市场申请”，而是一份”同赛道对打申请”。FUCASO手里的牌：它是全球首个商业化的全人源BCMA CAR-T——CARVYKTI的scFv是人源化的小鼠序列，FUCASO是全人源。全人源理论上免疫原性更低、体内存续更久，对应的是深度持久的缓解。更重要的是，驯鹿已经用香港验证过”南京生产、跨境供药”的完整链条。2024年12月，首位香港患者在香港玛丽医院输注了南京基地制备的FUCASO，海关、药监多部门联合监管的通道真实跑通。2025年11月在香港获批时，福可苏也成为首个获得国际PIC/S GMP认证的国产ATMP——TGA本身是PIC/S成员，接受PIC/S成员的检查报告，这份认证对澳洲的GMP审查是现成的通行证。更早之前，已有来自欧洲、澳洲、东南亚等地的海外患者专程来华接受这款CAR-T的治疗，澳大利亚患者也在其中。从香港到新加坡，再到悉尼，这套模式的辐射半径正在被一步步拉大。 TONACEA 04 如果澳洲上市成功对中国biotech意味着什么往小了说，是驯鹿一家公司的里程碑。往大了说，是三个层面的价值。第一层，监管信用。TGA的SRA地位决定了，拿到它的批准比拿到大多数国家的批准更有含金量。一款产品能同时通过NMPA、HSA、TGA的审评，再去谈FDA申报、谈欧洲合作，说服成本显著下降。对BD而言，海外已获批上市的产品，license-out的估值逻辑和临床阶段资产完全不同——这是可以直接折算成交易对价的。第二层，模式验证。自体CAR-T是重资产、个性化制造的生意，“境内生产、境外输注”一直是行业讨论的方向，但真正做到的极少。驯鹿在香港跑通第一步，在澳洲如果跑通第二步，等于证明中国细胞治疗的制造能力可以覆盖更远的市场。对行业来说，这是产能利用率和成本结构的实质正面样本——产能不再只是成本中心，它可以变成出口竞争力。第三层，路径选择。中国CAR-T出海过去只有一条主流路径：把权益卖出去，让MNC替自己卖药。传奇给强生，驯鹿也给韩国GC Cell做过授权。但自主出海有个前提——权益得在自己手里。驯鹿2025年7月从信达生物买回福可苏的全球商业化权益，正是为了这个。此后新加坡获批、澳洲获受理，第二条路径逐渐成型：自主注册、自主商业化，先在亚太市场建立自己的品牌。两条路并不互斥，但对行业而言，多一条能走通的路，谈判桌上就多一分底气。这背后还藏着一层估值逻辑。资本市场给中国biotech估值，长期受制于”只有中国市场收入”的折价；一旦海外获批上市，收入模型里多出真金白银的海外贡献，估值锚点就会变。传奇生物凭CARVYKTI的全球销售撑起市值，就是最直接的参照。澳大利亚对中国创新药，曾经是个”神秘”的地方：它讲得清临床故事，却看不清上市收益。驯鹿把FUCASO递进TGA的那一刻，是在替整个行业把这个问题问明白——澳洲到底能不能成为中国创新药的下一个主战场。评估已经开始。答案不需要等太久。作者介绍肖生客本名刘肖，行诚生物商务副总裁，同写意首席品牌官，CSGCT（民非组织）秘书长

2026-08-20

·BioSpace

7 biopharma M&A deals where layoffs followed

iStock, lchumpitaz Workforce cuts this year at seven companies involved in recent mergers and acquisitions will cost over 1,300 employees their jobs. Affected businesses include Arcellx and Tourmaline Bio, acquired by Gilead Sciences and Novartis, respectively. So far in 2026, layoffs have hit at least seven biopharmas involved in a recent merger or acquisition. Those companies’ cuts will collectively wipe out a minimum of 1,359 employees’ jobs, according to BioSpace tallies. The largest workforce reduction is at CureVac—acquired by BioNTech—where 820 people will need to find other positions by the end of next year. Below, BioSpace looks at the seven M&A deals where layoffs followed in 2026, sometimes just days or weeks after the transactions closed. 1. Gilead Sciences and Arcellx Once Gilead Sciences closed its $7.8 billion acquisition of Arcellx, it didn’t take the pharma long to disclose it was slashing the biotech’s workforce. Worker Adjustment and Retraining Notification (WARN) Act notices in California and Maryland were dated April 30, just two days after Gilead announced it had completed the deal . The pharma is laying off 192 Arcellx employees, likely wiping out 87% of the biotech’s workforce, according to a BioSpace estimate based on a March 1 employee count . Most affected staff worked at Arcellx’s headquarters in Redwood City, California, where 108 people were let go effective June 30. In Rockville, Maryland, 84 employees are being laid off between June 30, 2026, and April 30, 2027. Mergers & acquisitions Gilead Doubles Down on CAR T With $7.8B Arcellx Acquisition The centerpiece of the takeover is anito-cel, a CAR T therapy under development for relapsed or refractory multiple myeloma. An FDA decision on the therapy is expected by December 2026. February 23, 2026 · 2 min read · Tristan Manalac Read more 2. BioMarin Pharmaceutical and Amicus Therapeutics In early May, two weeks after BioMarin Pharmaceutical announced completion of its $4.8 billion acquisition of Amicus Therapeutics, Amicus disclosed it will lay off 58 staffers from its Princeton, New Jersey, headquarters. The cuts could affect around 11% of the biotech’s workforce, according to a BioSpace estimate based on an employee count as of Dec. 31, 2025. The layoffs are effective from Aug. 7 to Oct. 30, 2026, according to the WARN notice . A BioMarin spokesperson told Fierce Pharma the layoffs link to the acquisition, noting that “As with any integration of this scale, we are carefully evaluating how to align our organizations for long-term success. This process has resulted in headcount reductions, particularly in areas where there is overlap.” Mergers & acquisitions BioMarin Pumps Up Revenue Goals With $4.8B Amicus Purchase BioMarin Pharmaceutical has faced a rocky road, promising and then backing off revenue targets and cutting assets that have underperformed. But Amicus’ rare disease portfolio is already bringing in $600 million annually. December 19, 2025 · 2 min read · Dan Samorodnitsky Read more 3. Novartis and Tourmaline Bio While Novartis completed its $1.4 billion acquisition of Tourmaline Bio in October 2025, Tourmaline did not disclose layoffs until four months later, in February. The company divulged in a WARN notice that it was letting go of 60 employees at its New York City headquarters, effective May 29. The cuts may have affected about 79% of the biotech’s workforce, according to a BioSpace estimate based on an employee count as of Aug. 1, 2025. In addition to letting employees go, Tourmaline also closed its headquarters, according to the WARN notice. The alert stated “merger” as the reason behind the closure. Mergers & acquisitions Novartis Deals in Cardio Again, Dropping $1.4B To Acquire Tourmaline Novartis has been investing heavily in its cardiovascular pipeline this year, forging partnerships with Flagship startup ProFound Therapeutics and China’s Argo Biopharmaceutical, among others. September 9, 2025 · 2 min read · Tristan Manalac Read more 4. BioNTech and CureVac BioNTech completed its $1.25 billion acquisition of CureVac in December 2025 and divulged layoffs five months later. In early May, BioNTech disclosed in a quarterly report that it will let go of about 820 people at CureVac by the end of next year. The workforce reduction could affect 83% of the biotech’s workforce, according to a BioSpace estimate based on an employee count as of Dec. 31, 2024, the most recent count filed with the SEC. In its quarterly report, BioNTech noted that it plans to exit operations at Germany-based CureVac’s German and international sites, which host clinical and commercial-scale mRNA manufacturing capacities as well as research and development and enabling functions. Legal BioNTech Attacked CureVac’s ‘Failed’ COVID Vaccine Program. The Rivals Are Now Merging BioNTech said in 2022 that it faced “threats of a groundless patent infringement suit” from a company that was “unable to bring to market any product to help in the fight against COVID-19.” Now, the mRNA biotech is buying that very company. June 18, 2025 · 4 min read · Nick Paul Taylor Read more 5. Biogen and Apellis Pharmaceuticals In June, one month after closing its $5.6 billion acquisition of Apellis Pharmaceuticals, Biogen told BioSpace it is cutting a “small number” of roles within its research arm related to discontinued Apellis programs. The company did not specify how many of the biotech’s employees are affected. Apellis had 739 employees as of Dec. 31, 2025. Biogen had conducted a comprehensive review of the biotech’s clinical and preclinical portfolio and, as a result, decided to pause or terminate investment in most legacy preclinical programs, a Biogen spokesperson told BioSpace . Mergers & acquisitions Biogen Secures ‘Running Start’ in Kidney Disease With $5.6B Apellis Buy In addition to delivering two approved medicines to Biogen’s portfolio, the acquisition of Apellis Pharmaceuticals will support the future launch of the pharma’s own kidney disease asset, currently in multiple Phase 3 trials. March 31, 2026 · 4 min read · Annalee Armstrong Read more 6. MindMaze Therapeutics and Relief Therapeutics Earlier this month, eight months after completing a reverse merger with Relief Therapeutics, MindMaze Therapeutics announced it had finished an organizational simplification involving disposal of Switzerland-based Relief’s legacy operations. MindMaze Chief Financial Officer Jeremy Meinen told BioSpace that “a handful” of Relief employees were let go and received notice periods of several months. Meinen explained that rather than close Relief’s legacy operations in Switzerland, which employed around 25 people, MindMaze found acquirers for those businesses. New ownership retained “substantially all” Relief employees, with some remaining at MindMaze and others let go, he said. Meinen declined to specify the number laid off or name the acquiring businesses. 7. Sanofi and Blueprint Medicines Sanofi and Blueprint Medicines had a long lag from deal closure to cuts. Earlier this month, 13 months after completing its $9.5 billion acquisition of Blueprint Medicines, Sanofi disclosed in a WARN notice that Blueprint is laying off about 229 employees in Cambridge, Massachusetts, where the subsidiary is based. Effective from Oct. 9, 2026, to June 25, 2027, the cuts could affect around 33% of Blueprint’s workforce, according to a BioSpace estimate based on an employee count as of April 15, 2025. In addition to the layoffs, the Cambridge facility will close Dec. 31, with “decommissioning work” happening through June 2027, according to the full WARN notice. As of Jan. 1, 2027, remaining Blueprint employees assigned to that location will start reporting to Sanofi’s U.S. office in Cambridge at 450 Water St. Mergers & acquisitions Sanofi Inks $9.5B Blueprint Buyout to Expand Rare Disease Portfolio Blueprint has a next-generation systemic mastocytosis treatment, called elenestinib, that Sanofi CEO Paul Hudson told analysts provides an “opportunity to grow through the ‘30s.” June 2, 2025 · 3 min read · Nick Paul Taylor Read more More layoffs could be ahead While it’s unknown how many more layoffs will follow recent M&A deals, it’s possible additional cuts are on the way given how transactions have ramped up in 2026. During H1, there were 52 mergers and acquisitions , up from 32 in H1 2025 , according to BioSpace tallies. Deals have continued into the second half of 2026, with at least 10 announced through Aug. 18. The largest transaction BioSpace reported is Vertex Pharmaceuticals’ $10 billion buyout of Crinetics Pharmaceuticals. One deal already linked to likely workforce cuts is the Supernus Pharmaceuticals and Indivior Pharmaceuticals merger announced at the start of this month. That business combination, expected to produce $2.2 billion in combined revenue, will likely result in “natural redundancies” in general and administrative roles, Supernus CEO Jack Khattar said during a recent investor call. Rockville, Maryland–based Supernus had  778 employees and North Chesterfield, Virginia–based Indivior 838 as of Dec. 31, 2025. M&A Supernus and Indivior merge to create CNS mega-company with 11 approved drugs Supernus Pharmaceuticals and Indivior Pharmaceuticals are outlining a combined expected $2.2 billion in annual revenue, plus $125 million in cost savings that will include “natural redundancies.” August 3, 2026 · 3 min read · Gabrielle Masson Read more Layoff numbers exclude contract development and manufacturing organizations, contract research organizations, tools and services businesses and medical device firms. To tally the cuts,  BioSpace  compiles data for known workforce reductions. The number of employees affected is identified or estimated through confirmation from company officials as well as information in company press releases,  Worker Adjustment and Retraining Notification (WARN) Act  notices, SEC filings and other media outlets’ reports. Not all companies disclose downsizing, and some share only the percentage of staff affected. Some biopharmas provide total numbers retrospectively rather than disclosing individual workforce reductions as they happen.  .responsive-container { display: flex; flex-wrap: wrap; border: 1px solid #ededed; font-family: Helvetica, Arial, Sans-Serif; padding: 20px 20px 10px 20px; } .column-left { flex: 1; max-width: 45%; padding: 20px 20px 10px 20px; } .column-right { flex: 2; padding: 20px 20px 10px 20px; } @media (max-width: 768px) { .column-left, .column-right { max-width: 100%; flex: 100%; padding: 10px 0; } } Subscribe to Career Insider! Job market trends, layoffs and career advice to manage your life sciences career hbspt.forms.create({ region: "na1", portalId: "4413123", formId: "7c63cc9f-e9ed-42c4-8c81-fa1538ee1421", onFormSubmitted: function($form, data) { window.dataLayer = window.dataLayer || []; window.dataLayer.push({ 'event': 'GTMevent', 'event_name': 'newsletter_sign_up' }); } });

并购疫苗临床3期

2026-08-19

·全球GCT研究

吉利德从CAR-T守成到全赛道突围？

2025年细胞治疗$18亿(-7%)·Yescarta/Tecartus双引擎(Kite占CAR-T市场40%)·$78亿收购Arcellx(anito-cel 96% ORR)·$3.5亿收购Interius·MNC全维度对比(技术平台/专利/CMC/生产/成本/临床/推广/商保/Medicare/盈利)·2026-2036展望 GCT前沿·Gilead/Kite官方/ASH/ASCO/FierceBiotech·📖 约 7068 字 · 17 分钟·🔗 Gilead官方 2025年报一、引言:CAR-T帝国的"守成与突围" 吉利德(Gilead)是细胞治疗领域"最资深的大厂":2017年以$119亿收购Kite Pharma,一举拿下Yescarta(全球首批CAR-T之一)与Tecartus,建立了占全球CAR-T市场约40%的领导地位[^4][^8]。但2025年的财务数据揭示了"守成的压力":细胞治疗销售$18亿(-7%),Yescarta/Tecartus面临BMS(Breyanzi/Abecma)与传奇/J&J(Carvykti,2025 $18.87亿+50%)的激烈竞争[^1][^3][^13]。面对压力,吉利德在2026年初连续打出"突围组合拳":2月23日宣布$78亿收购Arcellx——拿下BCMA CAR-T anito-cel(iMMagine-1:96% ORR/74% CR,FDA决策在即)[^5][^6][^9];此前2025年8月以$3.5亿收购Interius布局体内CAR-T(INT2104,欧洲首个体内CAR-T临床)[^8][^11]。累计CGT投资超$200亿,吉利德正从"CAR-T守成者"向"全赛道布局者"转型。如果你是一名患者或家属:多发性骨髓瘤患者可关注anito-cel——iMMagine-1数据显示96%缓解率、74%完全缓解,是潜在best-in-class;若2026 Q1获批,将是MM患者的新选择[^5][^6][^9]。如果你是一名临床医生:你需要理解吉利德的三线布局:已上市(Yescarta/Tecartus)、即将获批(anito-cel)、未来(INT2104体内CAR-T)——以及anito-cel vs Carvykti/Abecma的临床定位差异[^1][^3][^9]。如果你在biotech新药研发:吉利德的$78亿Arcellx收购+$3.5亿Interius收购,验证了"已上市产品现金流+下一代技术并购"的CGT战略范式;anito-cel的96% ORR数据是CAR-T"疗效天花板"的再定义[^5][^6][^8][^9]。二、吉利德CGT底气分析表1|吉利德细胞治疗板块:2025年财务与资产全景维度数据解读2025年产品销售额(不含Veklury)$280亿(+4%) HIV $208亿(+6%),Biktarvy $143亿(+7%)——现金牛支撑CGT投入[^1][^2]细胞治疗销售(2025)$18亿(-7%) Yescarta+Tecartus合计;竞争加剧(Tecartus全年$3.44亿,-15%)[^1][^3]Kite市场地位占全球CAR-T市场约40% (2026初) Yescarta+Tecartus双引擎仍是全球CAR-T领导品牌[^4]Arcellx收购(2026.2.23)$78亿($115/股现金+$5 CVR) anito-cel(BCMA CAR-T)全权控制;FDA决策在即[^5][^6][^7]Interius收购(2025.8)$3.5亿体内CAR-T平台(INT2104,欧洲首个临床)[^8]CGT总投资 $78亿+$3.5亿+历史Kite $119亿(2017) 累计超$200亿——全球CGT投资最重的Big Pharma之一底气来源:(1)财务引擎——2025年产品销售额$280亿(+4%),HIV板块$208亿(Biktarvy $143亿+7%)持续提供现金流,支撑CGT的$78亿级并购[^1][^2];(2)制造能力——Kite全球CAR-T制造网络(美国/欧洲/日本)是竞争对手难以复制的资产,也是anito-cel商业化的基础设施[^4][^8];(3)临床与注册经验——Yescarta/Tecartus的全球注册与真实世界数据积累,使吉利德拥有CAR-T从临床到商业化的全流程know-how[^1][^12];(4)战略定力——累计$200亿+CGT投资,是"用HIV利润养CGT未来"的长期主义[^1][^5][^8]。三、Kite双引擎:Yescarta与Tecartus 表2|吉利德CAR-T管线全景(2026) 管线技术靶点适应症阶段关键数据Yescarta (axicabtagene) 自体CAR-T(γ-逆转录病毒) CD19 r/r LBCL、r/r FL已上市(2017) 2025约$14.56亿(推算:$18亿-Tecartus $3.44亿);全球最畅销CAR-T之一[^1][^3][^4]Tecartus (brexucabtagene) 自体CAR-T(γ-逆转录病毒) CD19 r/r MCL、r/r B-ALL已上市(2020)2025 $3.44亿(-15%,官方) ;唯一3L CD19 CAR-T[^1][^3][^8]anito-cel (Arcellx) 自体CAR-T(CMA-创新架构) BCMA r/r多发性骨髓瘤(4L)BLA已提交,FDA决策2026 Q1iMMagine-1:96% ORR、74% CR/sCR、MRD-95%(15.9月随访);与CARTITUDE-1(97.9% ORR)同数量级 [^5][^6][^9][^19]KITE-753 自体CAR-T(双顺反子) 双靶点血液瘤(克服抗原异质性) Ph1/2 双顺反子设计防复发;ASCO/EHA 2026展示[^10]INT2104 (Interius) 体内CAR-T(靶向LV) CD19 B细胞恶性肿瘤 Ph1(2025.1欧洲首个) 体内生成CD4+/CD8+CAR-T[^8][^11]ASH 2025三大新CAR-T Kite下一代管线多样血液瘤扩展临床早期 anito-cel领衔的下一代组合[^12] 图2|CAR-T主要产品2025年销售对比(吉利德双引擎vs竞品) · 查看原文表5|Kite在研管线/临床试验全景与专利护城河维度内容已上市 Yescarta(2017)/Tecartus(2020,2026.4获FDA完全批准MCL)[^20]在研管线KITE-363、KITE-753(双顺反子bicistronic CAR-T,克服肿瘤抗原异质性防复发) ;ASH 2025展示新一代双顺反子数据[^10][^21]临床试验8项active临床试验 (双抗原靶向等);覆盖LBCL/FL/MCL/ALL/MM[^22]核心专利群 CAR构建专利(CD19/BCMA)、双顺反子载体专利、制造工艺专利、γ-逆转录病毒载体优化专利——8年积累的"制造+构建"双专利群[^8][^21]技术护城河全球最大自体CAR-T制造网络(美/欧/日)+8年临床/注册/商业化know-how+40%市场份额 ——竞争对手难以复制的"规模+经验"双壁垒[^4][^8] Kite技术护城河深度分析:(1)制造护城河——全球最大自体CAR-T制造网络(美/欧/日),是8年规模化生产的"经验曲线"积累,新进入者难以复制;(2)专利护城河——CAR构建+双顺反子载体+制造工艺的三层专利群,覆盖从"分子到工厂"全链条[^8][^21];(3)临床护城河——8项active临床试验+美欧日授权治疗中心网络持续扩网(日本Yescarta授权机构已达70家),临床/注册/商业化的全流程know-how[^22][^29];(4)产品护城河——Tecartus 2026.4获FDA完全批准(MCL),Yescarta全球最畅销CAR-T之一——"40%市场份额+8年经验"是Kite最深的护城河[^4][^8][^20]。双引擎现状:Yescarta(2025约$14.56亿)仍是全球最畅销CAR-T之一,但增速放缓;Tecartus(2025全年$3.44亿,-15%)面临同类竞争[^1][^3][^4]。关键判断:吉利德细胞治疗销售下滑(-7%)是"成熟产品周期+竞争加剧"的双重结果,但Kite仍占全球CAR-T市场约40%——问题不是"帝国衰落",而是"如何找到下一个增长引擎"[^1][^4][^8]。四、Arcellx $78亿收购:anito-cel深度解读交易细节:2026.2.23吉利德宣布以$115/股现金+$5 CVR(合计约$78亿)收购Arcellx,获得anito-cel完全控制权——这是吉利德继Kite之后最大的细胞治疗收购[^5][^6][^7]。表6|Arcellx在研管线/临床试验全景与专利护城河维度内容核心管线anito-cel(CART-ddBCMA) :首个BCMA CAR-T采用D-Domain结合域;iMMagine-1 Ph2/3:96% ORR、74% CR/sCR、MRD-95%;Ph2另报97% ORR、93.1% MRD-[^5][^6][^23]技术平台D-Domain CAR(ddCAR)平台 :小型化专有靶向结合域,更高特异性/更优药代;TANDEM 2026展示D-Domain高靶点特异性[^24][^25]临床进展 BLA已提交(4L MM),FDA决策2026 Q1;前线MM扩展试验推进[^7][^9]核心专利群D-Domain结合域专利+ddCAR架构专利+BCMA CAR专利 ——小型化结合域是差异化核心IP[^24][^25]技术护城河D-Domain平台的可扩展性 (结合域模块化替换→多靶点CAR-T快速开发)+anito-cel临床数据领先——吉利德$78亿收购即为此护城河定价[^5][^24] Arcellx技术护城河深度分析:(1)D-Domain平台护城河——小型化专有靶向结合域(ddCAR)是区别于传统scFv CAR的核心IP,模块化替换支持多靶点快速开发[^24][^25];(2)数据护城河——iMMagine-1的96% ORR/74% CR与Ph2的97% ORR/93.1% MRD-双重验证,是MM领域最强数据集之一[^5][^6][^23];(3)专利护城河——D-Domain结合域+ddCAR架构+BCMA CAR三层专利,覆盖"结合域-架构-靶点"全链条[^24];(4)吉利德$78亿收购的本质——买的是"可扩展的D-Domain平台+已验证的anito-cel数据",而非单一产品——这是对平台型CAR-T资产的定价[^5][^24]。 anito-cel(iMMagine-1)数据解读:Ph2/3关键研究显示96% ORR、74% CR/sCR、MRD阴性95%(中位随访15.9个月),且缓解随时间持续加深——这一数据在r/r MM领域与Carvykti(CARTITUDE-1:ORR 97.9%/sCR 82.5%)处于同一数量级,MRD阴性率95%为差异化亮点;与Abecma(KarMMa)相比缓解率更优[^5][^6][^9][^19]。BLA已作为4L MM提交,FDA决策预期2026 Q1[^7][^9]。战略意义:anito-cel若获批,将成为吉利德在MM领域的"破局者",正面挑战Carvykti($18.87亿/2025)的霸主地位[^5][^6][^13]。五、体内CAR-T布局:Interius收购表7|Interius在研管线/临床试验全景与专利护城河维度内容核心管线INT2104 (B细胞恶性肿瘤,CD19靶向):体内CAR-T,单次IV输注生成CAR-T;2025.1欧洲首个体内CAR-T临床[^8][^11][^26]技术平台靶向慢病毒LV平台 :CD3/CD5/CD7识别包膜,体内同时生成CD4+/CD8+CAR-T;无需清淋/离体培养[^11][^26]临床进展 Ph1(欧洲,2025.1启动);Kite $3.5亿收购后整合推进[^8][^27]核心专利群靶向LV包膜工程专利+体内T细胞编程专利 (Mark Foundation portfolio背景)[^27][^28]技术护城河"首个进入临床的体内CAR-T"先发地位 +单次IV可及性革命(免2-4周制备)——吉利德以$3.5亿低门槛锁定体内CAR-T入场券[^8][^26][^27] Interius技术护城河深度分析:(1)先发护城河——"首个进入临床的体内CAR-T"(2025.1欧洲),INT2104的Ph1数据(2026-2027)将定义体内CAR-T的疗效基准[^8][^26];(2)技术护城河——靶向LV包膜工程(CD3/CD5/CD7识别)+体内CD4+/CD8+双生成,单次IV可及性革命(免2-4周制备)[^11][^26];(3)专利护城河——靶向LV包膜工程+体内T细胞编程专利群(Mark Foundation背景)[^27][^28];(4)吉利德$3.5亿收购的战略价值——以极低成本锁定体内CAR-T入场券,与$78亿的Arcellx(已验证资产)形成"高风险高回报+低风险已验证"的互补组合[^8][^27]。 2025年8月,吉利德旗下Kite以$3.5亿收购Interius BioTherapeutics,获得体内CAR-T平台——其核心管线INT2104于2025.1启动欧洲首个体内CAR-T临床,通过靶向LV在体内同时生成CD4+/CD8+CAR-T[^8][^11]。战略意义:吉利德是全球最早布局体内CAR-T的Big Pharma之一(早于Lilly的Kelonia/Orna收购),INT2104的Ph1数据(2026-2027)将是吉利德体内CAR-T战略的试金石[^8][^11]。六、吉利德 vs 竞品:CAR-T/体内CAR-T全格局表3|吉利德 vs 竞品CAR-T/体内CAR-T格局对比(2026) 维度吉利德(Kite) 传奇/J&J BMS Lilly已上市产品 Yescarta+Tecartus(2款) Carvykti(1款,共同开发) Breyanzi+Abecma(2款) 无2025销售合计 $18亿(-7%) Carvykti $18.87亿(+50%+) Breyanzi $13.58亿+Abecma $5.5亿 —在研关键资产anito-cel(BLA)+KITE-753+INT2104(体内) C-CAR031等(实体瘤) 多管线KLN-1010+ORN-252(体内)体内CAR-T Interius INT2104(Ph1,欧洲首个) —(注:曾与Kelonia合作已失) Orbital(RNA平台)Kelonia+Orna双引擎($94亿)差异化优势制造产能+临床数据积累+CAR-T领导品牌 Carvykti高速增长+MM深度布局多适应症覆盖体内CAR-T最激进核心短板细胞治疗销售下滑(-7%);Yescarta竞争承压依赖单一产品;实体瘤待验证销售增长放缓无已上市CAR-T 图1|吉利德细胞基因治疗板块:从CAR-T帝国到全赛道布局 · 查看原文竞争格局判断:(1)已上市CAR-T——吉利德($18亿) vs BMS($19亿+) vs 传奇/J&J($18.87亿单产品):三强并立,Carvykti增速最快(+50%),吉利德承压(-7%)[^1][^3][^13];(2)在研关键资产——吉利德anito-cel(BLA)是MM领域最强数据;传奇C-CAR031(实体瘤)是差异化方向[^5][^9];(3)体内CAR-T——吉利德INT2104(Ph1)与Lilly双引擎($94亿)领跑,Umoja/J&J-Sail跟进[^8][^11][^14];(4)综合判断:吉利德是"已上市+即将获批+体内布局"三维度最均衡的玩家[^1][^5][^8]。七、MNC全维度对比:吉利德的真实竞争力表4|吉利德 vs 强生 vs 诺华 vs BMS vs 礼来:CGT全维度对比(2026) 维度吉利德(Kite) 强生(传奇) 诺华 BMS 礼来已上市CAR-T Yescarta+Tecartus(2款) Carvykti(共同开发) Kymriah(全球首个) Breyanzi+Abecma(2款) 无2025销售合计 $18亿(-7%) Carvykti $18.87亿(+50%)Kymriah $3.81亿(持续下滑,竞争压力) Breyanzi $13.58亿+Abecma $5.5亿 —技术平台自体CAR-T(γ-RV)+体内LV(Interius)+双顺反子(KITE-753) 自体CAR-T(慢病毒)+实体瘤CAR-T(C-CAR031) 自体CAR-T+T-Charge(快速制造) 自体CAR-T(慢病毒)+RNA平台(Orbital) 体内CAR-T双引擎(Kelonia iGPS+Orna circRNA)核心专利 CAR构建+制造工艺专利群(8年积累) BCMA CAR专利(Carvykti)+GPC3专利 CD19 CAR奠基专利(全球首个定价基准) CD19/BCMA CAR专利群 circRNA环化/LNP靶向/iGPS包膜专利CMC复杂度自体CAR-T(标准化平台,全球3大制造基地) 自体CAR-T(慢病毒,产能扩产中) 自体CAR-T(早期平台,产能领先) 自体CAR-T(2产品平台) 体内:病毒+RNA双CMC(建设中)规模生产全球最大CAR-T制造网络(美/欧/日) 全球扩产(比利时/中国/美国) 美国+欧洲+亚太基地美国+欧洲基地 LNP产能可复用(无自体制造)制备成本目标自体$10-15万(规模效应最优) 自体$10-15万自体$10-15万;T-Charge降本自体$10-15万体内目标$3-15万(革命性降本)管线/适应症血液瘤(LBCL/FL/MCL/ALL)+MM(anito-cel)+体内 MM+实体瘤(GPC3) ALL/DLBCL+自免扩展 LBCL/CLL/MM+自免 MM(KLN-1010)+自免(ORN-252)美国临床能力顶级(300+临床中心,Kite网络) 顶级(传奇合作网络) 顶级(全球首个CAR-T) 顶级(多适应症) 强(快速推进)全球临床能力美/欧/日/中多中心美/欧/中全球最广(30+国家) 美/欧/日美/欧/亚太(自免网络)美国市场推广最强(Kite商业团队+血液瘤深耕) 强(J&J肿瘤团队) 强(但Kymriah下滑) 强(多产品协同) 新进入者(需自建)欧洲推广强(欧洲获批+本地制造) 强最强(欧洲总部) 强建设中费用控制强(单一业务聚焦,费用率优化) 中(合作分成) 中(多业务分摊) 中强(现金流充沛)美国商保谈判成熟(Yescarta疗效挂钩协议,6款FDA CAR-T均采用outcome-based调整) [^15] 成熟(Carvykti) 成熟(首个定价基准) 成熟新进入(需建立)Medicare/Medicaid谈判成熟(MS-DRG 018覆盖,与CMS谈判经验) [^16] 成熟成熟成熟新进入盈利市场空间美国唯一第一梯队($37-46万定价×40%份额) 美国+欧洲全球(但产品下滑) 美国+欧洲美国(体内$3-15万×大规模) 全维度对比的核心结论:(1)制造与商业化是吉利德的护城河——全球最大CAR-T制造网络(美/欧/日)+Kite商业团队+8年血液瘤深耕,使Yescarta/Tecartus虽面临竞争仍守住40%市场份额[^1][^4][^8];(2)支付谈判能力成熟——6款FDA CAR-T(含Yescarta)均已采用outcome-based疗效挂钩支付调整,吉利德与商保/CMS的谈判经验是礼来等新进入者不具备的[^15][^16];(3)anito-cel是"产品补强"而非"平台补强"——吉利德用$78亿补最强MM数据,延续"成熟平台+最强资产"战略[^5][^6];(4)对比礼来的"平台激进"与吉利德的"资产稳健"——礼来$94亿押注体内平台(远期),吉利德$78亿押注anito-cel(近期商业化)+$3.5亿体内布局(远期),风险收益结构更均衡[^5][^8][^14];(5)盈利空间判断——美国仍是唯一第一梯队市场($37-46万定价×40%份额),吉利德在"美国商保+Medicare谈判+欧洲推广"三维度均处成熟期,而礼来需从零建立[^15][^16][^17]。吉利德的真实短板:(1)细胞治疗销售下滑(-7%)暴露"产品老化"风险;(2)anito-cel上市后需与Carvykti正面争夺MM市场份额与支付额度;(3)体内CAR-T(INT2104)落后Lilly双引擎的资本投入($3.5亿 vs $94亿)——吉利德选择"小步快跑",礼来选择"重注押注"[^1][^5][^8][^14]。八、2026年关键里程碑与顶刊数据 (1)anito-cel FDA决策(2026 Q1)——iMMagine-1数据(96% ORR/74% CR)支撑的BLA审评,是吉利德2026年最大催化剂[^7][^9];(2)ASH 2025——Kite展示anito-cel领衔的三大新CAR-T,确立下一代管线信心[^12];(3)ASCO/EHA 2026——KITE-753(双顺反子)等新数据展示,验证"克服抗原异质性"设计[^10];(4)INT2104 Ph1数据——体内CAR-T的欧洲临床进展,2026-2027读出[^8][^11]。九、挑战与风险 (1)细胞治疗销售下滑——Yescarta/Tecartus面临Breyanzi/Carvykti竞争,2026年压力持续(Yahoo:吉利德预计竞争压力延续)[^1][^3];(2)anito-cel商业化不确定性——FDA决策、定价(对标Carvykti $46.5万)、与Carvykti的正面竞争[^5][^9][^13];(3)CMC与产能——自体CAR-T制造复杂,anito-cel放量需Kite产能扩容;体内CAR-T(INT2104)的慢病毒CMC是共性瓶颈[^8][^11];(4)体内CAR-T竞争——Lilly $94亿双引擎/J&J-Sail/Umoja竞速,INT2104需证明差异化[^8][^14];(5)支付环境——CAR-T $37-46万定价,美国支付体系虽领先但商保/Medicare谈判压力上升[^13]。十、2026-2036展望 2026-2028:anito-cel获批上市(MM 4L→前线推进);INT2104 Ph1数据读出;KITE-753进入Ph2;细胞治疗销售企稳回升。 2028-2032:anito-cel挑战Carvykti MM霸主地位;体内CAR-T(INT2104)进入Ph2/3;吉利德CGT销售有望突破$40亿。 2032-2036:体内CAR-T获批;"已上市CAR-T+anito-cel+体内CAR-T"三线并进,吉利德CGT收入剑指$100亿——从"HIV帝国"进化为"HIV+CGT双帝国"[^1][^5][^8][^13]。十一、给各方建议(三类读者全覆盖)11.1 给患者与家庭 (1)r/r MM患者关注anito-cel——96% ORR/74% CR数据(2026 Q1可能获批);(2)接受CAR-T治疗前确认:适应症匹配+临床试验机会;(3)了解Yescarta/Tecartus的长期随访数据与真实世界证据[^5][^6][^9]。11.2 给临床医生 (1)掌握anito-cel vs Carvykti/Abecma的MM治疗定位(4L vs 前线);(2)关注iMMagine-1的MRD阴性95%数据对MRD指导治疗的启示;(3)跟踪INT2104体内CAR-T的临床进展[^5][^6][^8][^9]。11.3 给biotech新药研发从业者 (1)吉利德战略范式:已上市产品现金流($18亿)+下一代并购(Arcellx $78亿/Interius $3.5亿)双轮驱动;(2)anito-cel的96% ORR证明"数据驱动并购"逻辑——并购估值锚定关键临床数据;(3)体内CAR-T是下一战场,INT2104与Lilly双引擎的竞争将定义格局[^5][^6][^8][^11][^14]。十二、结语:从"HIV帝国"到"CGT双引擎" 吉利德的故事是Big Pharma布局CGT的"标准答案":用HIV现金牛($208亿)供养CGT梦想,用Kite建立CAR-T帝国(占市场40%),用$78亿收购anito-cel迎接MM之战,用$3.5亿布局体内CAR-T迎接下一代[^1][^4][^5][^8]。 2025年的$18亿(-7%)不是"帝国衰落",而是"新旧动能转换"的阵痛——anito-cel(96% ORR)与INT2104(体内CAR-T)正是新动能[^1][^5][^9][^11]。当CAR-T从"血液瘤三强并立"走向"MM正面决战+体内下一代",吉利德正用最深的积累与最果断的并购,争取CGT时代的"帝国续章"[^5][^8][^13][^14]。 📚 参考文献溯源 [1]Gilead官方2025年报:全年产品销售额(不含Veklury)$280亿(+4%),HIV $208亿(+6%),Biktarvy $143亿(+7%),细胞治疗$18亿(-7%) · Gilead Sciences [2]StockTitan/Gilead 8-K:2025年产品销售额(不含Veklury)增至$280亿(+4%),HIV增长6%至$208亿 · StockTitan/Gilead [3]Yahoo Finance/Gilead:2025全年Tecartus销售$344M(-15%);吉利德预计细胞治疗竞争压力延续 · Yahoo Finance [4]BusinessModelCanvas/Kite:2026初Kite占全球CAR-T市场约40%;Yescarta 2025超$19亿(注:与官方口径有出入,以官方$18亿合计为准) · BusinessModelCanvas [5]Gilead官方(2026.2.23):$78亿收购Arcellx($115/股+$5 CVR)——最大化anito-cel长期价值 · Gilead Sciences [6]Businesswire/Arcellx(2025.12):iMMagine-1新数据——anito-cel 96% ORR、74% CR/sCR、MRD-95%(中位随访15.9个月,缓解持续加深) · Businesswire [7]BioSpace/FierceBiotech:anito-cel BLA已提交(4L MM),FDA决策预期2026 Q1;吉利德$78亿收购锁定审批前窗口 · BioSpace [8]Barchart/DelveInsight:Kite $3.5亿收购Interius(2025.8)——体内CAR-T平台;Tecartus仍是唯一3L CD19 CAR-T · Barchart/DelveInsight [9]OncLive/Precision Medicine Online:anito-cel iMMagine-1 97% ORR(OncLive口径)/96% ORR;Gilead预期FDA决策2026 Q1 · OncLive [10]Kite官方(2026.5):ASCO/EHA 2026展示KITE-753(双顺反子自体CAR-T,克服抗原异质性)等新数据 · Kite Pharma [11]PubMed 40581818(Andorko JI,2025):INT2104体内生成CD4+/CD8+CAR-T(Interius靶向LV平台) · PubMed · PMID:40581818 [12]Kite官方ASH 2025:Gilead/Kite展示anito-cel领衔的三大新CAR-T(血液瘤治疗变革) · Kite Pharma [13]GCT前沿8.9《MNC自免/CGT》专题:2025年Carvykti $18.87亿、Breyanzi $13.58亿、Yescarta约$14.56亿(推算)、Tecartus $3.44亿——CAR-T销售格局基线 · GCT前沿专题 [14]GCT前沿8.17《Lilly体内CAR-T》专题:Lilly $94亿双引擎(Kelonia $70亿+Orna $24亿)体内CAR-T战略;Umoja/J&J-Sail跟进 · GCT前沿专题 [15]HMPI 2026:CAR-T治疗成本分析——6款FDA CAR-T(Yescarta/Tecartus/Carvykti/Abecma/Breyanzi/Kymriah)均采用outcome-based疗效挂钩支付调整 · HMPI [16]Bioinformant:Yescarta美国定价$373,000、Kymriah $475,000(ALL)/$373,000(DLBCL);美国CAR-T报销体系(MS-DRG等) · Bioinformant [17]Grand View Research:CAR-T市场2025 $58亿→2026 $69亿→2033 $223亿;FactMR预测2036 $545亿 · Grand View Research [18]DelveInsight/Novartis 2025年报:KYMRIAH净销售$381M,因竞争持续下滑;诺华2025年持续经营净销售额$545亿 · DelveInsight/Novartis年报 [19]OncLive 2026:CARTITUDE-4长期数据——cilta-cel(Carvykti)标准风险MM 2.5年PFS率80.5%;CARTITUDE-1 ORR 97.9%/sCR 82.5% · OncLive [20]Kite官方(2026.4.2):FDA完全批准Tecartus用于r/r套细胞淋巴瘤(MCL) · Kite Pharma [21]Kite官方ASH 2025:展示新一代双顺反子CAR-T(KITE-363/KITE-753)数据——克服肿瘤抗原异质性 · Kite Pharma [22]Kite Clinical Trials:8项active临床试验(双抗原靶向CAR-T等) · Kite Clinical Trials [23]MedPath 2026:anito-cel Ph2 97% ORR、93.1% MRD阴性(r/r MM,2026商业化目标) · MedPath [24]Gilead官方/DDW:Arcellx D-Domain CAR(ddCAR)技术平台——专有靶向结合域,更高特异性;anito-cel为CART-ddBCMA · Gilead/DDW [25]Businesswire/TANDEM 2026:Arcellx晚期突破性报告——anito-cel D-Domain结合域独特高靶点特异性 · Businesswire/TANDEM [26]BioProcess Intl/Kite:Interius体内平台——单次IV输注慢病毒递送CAR基因;INT2104为B细胞恶性肿瘤Ph1 · BioProcess International [27]Pharmaceutical Technology:Kite $3.5亿收购Interius(2025.8)——首个进入临床的体内CAR-T公司整合入Kite · Pharmaceutical Technology [28]Mark Foundation:Interius为Mark Foundation portfolio公司;体内平台单次注射提升可及性 · Mark Foundation [29]Gilead官方2025年报(2026.2.10):Q4细胞治疗$458M(-6%);Tecartus全年$344M(-15%);LinkedIn/Cell Therapy:日本Yescarta授权机构达70家 · Gilead Sciences 细胞基因治疗前沿每日一篇 CGT 顶刊深度解读 · 数据源自 Nature/Cell/Science/Nat Biotechnol/ASGCT/ESGCT/AACR 内容仅供学术交流，不构成医疗建议

100 项与阿尼托卡布他基因自体淋巴细胞相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
难治性多发性骨髓瘤	申请上市	美国	Gilead Sciences, Inc.	2026-02-23
复发性多发性骨髓瘤	申请上市	美国	Gilead Sciences, Inc.	2026-02-23
多发性骨髓瘤	临床3期	美国	Arcellx, Inc.	2024-08-23
多发性骨髓瘤	临床3期	美国	Kite Pharma, Inc.	2024-08-23
多发性骨髓瘤	临床3期	日本	Arcellx, Inc.	2024-08-23
多发性骨髓瘤	临床3期	日本	Kite Pharma, Inc.	2024-08-23
多发性骨髓瘤	临床3期	澳大利亚	Arcellx, Inc.	2024-08-23
多发性骨髓瘤	临床3期	澳大利亚	Kite Pharma, Inc.	2024-08-23
多发性骨髓瘤	临床3期	奥地利	Arcellx, Inc.	2024-08-23
多发性骨髓瘤	临床3期	奥地利	Kite Pharma, Inc.	2024-08-23

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT05396885 (iMMagine-1, ASH2025 \| NEWS 1 \| NEWS 2) 人工标引	临床2期	复发性多发性骨髓瘤 \| 难治性多发性骨髓瘤	117	Anitocabtagene autoleucel	艱網觸觸齋醖艱蓋獵醖(廠廠窪衊築願鬱繭製蓋) = 糧蓋觸鏇網獵襯襯選製艱鑰鏇網鑰廠繭觸餘窪 (淵淵範網夢齋鏇膚淵夢 ) 更多	积极	2025-12-06
NCT05396885 (iMMagine-1, EHA2025)	临床2期	复发性多发性骨髓瘤 BCMA	86	Anitocabtagene autoleucel (anito-cel)	蓋醖夢襯繭壓鹹醖夢網(鏇齋衊膚淵廠簾蓋製壓) = 鹽壓構鬱廠獵獵夢鏇夢壓獵餘觸製簾獵構壓繭 (觸簾蓋齋獵襯製簾襯範 ) 更多	积极	2025-05-14
NCT04155749 (ASH2024) 人工标引	临床1期	多发性骨髓瘤	38	Anitocabtagene autoleucel (anito-cel)	夢襯壓壓蓋築齋壓糧簾(鏇鹹積壓顧鏇糧糧積獵) = 襯選糧願構繭繭選齋遞積衊淵窪壓網齋鹽淵簾 (觸網蓋構繭觸齋壓觸窪 ) 更多	积极	2024-12-09
NCT05396885 (iMMagine-1, PipelineReview) 人工标引	临床2期	多发性骨髓瘤	98	anitocabtagene autoleucel	繭蓋艱憲簾積壓網壓鬱(膚窪構醖簾範壓製獵憲) = 網醖廠鹽鏇蓋膚網範淵壓廠簾廠醖襯積構鬱壓 (艱顧襯窪願窪鏇淵衊選 ) 更多	积极	2024-12-09
NCT05396885 (iMMagine-1, ASH2024) 人工标引	临床2期	多发性骨髓瘤末线	58	Anitocabtagene autoleucel	觸願鹹網膚鹽艱廠鏇艱(顧遞蓋鏇繭鹹鑰鏇醖鑰) = 構艱醖淵憲窪願淵艱鑰願製範壓選鬱襯簾網廠 (網襯選窪糧簾憲夢鏇獵 ) 更多	积极	2024-12-09
NCT04155749 (IMS2024 \| NEWS) 人工标引	临床1期	多发性骨髓瘤	38	anitocabtagene autoleucel	簾構艱簾鏇簾廠構鑰獵(壓醖淵選鏇醖襯鑰窪鏇) = One grade 5 adverse event (AE) of unrelated cardiac arrest attributed to a non-study drug overdose occurred post study. The most common grade 3/4 hematologic AEs (n = 38) that were not attributable to cytokine release syndrome or immune effector cell-associated neurotoxicity syndrome were decreased neutrophil count (81.6%), anemia (57.9%), and thrombocytopenia (42.1%). Among non-hematologic AEs, the most common were hypertension (7.9%), increased aspartate aminotransferase levels (5.3%), and cellulitis (5.3%). 鬱廠鹽壓遞簾選製蓋範 (壓艱積齋獵鑰繭夢淵壓 )	积极	2024-09-24
NCT04155749 (IMS2024 \| NEWS) 人工标引	临床1期	多发性骨髓瘤	38	anitocabtagene autoleucel (patients with extramedullary disease)		积极	2024-09-24
NCT06413498 (iMMagine-3, SOHO2024)	临床3期	多发性骨髓瘤	-	Anito-cel	淵製廠構願繭遞艱繭繭(願選艱鏇艱繭襯艱淵願) = 製範壓獵觸醖膚願憲網築齋齋築壓簾憲鹽製觸 (廠願鹹衊鏇糧蓋壓憲獵 ) 更多	积极	2024-09-04
NCT04155749 (EHA 12024 \| EHA 22024) 人工标引	临床1期	多发性骨髓瘤末线	40	Anitocabtagene autoleucel (anito-cel)	鬱願繭淵積選觸網窪廠(壓齋淵願夢獵襯齋選顧) = 夢積廠鑰齋觸窪壓鑰鹹餘願淵餘襯鹽築齋願顧 (繭顧網艱顧遞憲齋襯構 ) 更多	积极	2024-05-14
NCT04155749 (ASH2023) 人工标引	临床1期	多发性骨髓瘤末线	38	CART-ddBCMA	觸艱憲襯鬱蓋襯廠壓廠(鏇繭醖遞糧鬱築壓憲廠) = 築窪淵鹽積壓築願網膚遞憲憲窪窪衊膚鬱艱範 (糧觸積鏇選選製襯獵簾 ) 更多	积极	2023-12-11
NCT04155749 (PRNewswire) 人工标引	临床1期	多发性骨髓瘤	38	CART-ddBCMA	夢築範構餘鹽廠衊鏇醖(鬱淵獵蓋獵繭鬱範範觸) = 餘膚築齋衊遞簾廠憲窪衊廠壓鑰憲選壓製鏇膚 (築憲鏇醖簾鬱鏇糧獵壓 ) 更多	积极	2023-12-08